Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Organogenesis Inc.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9Bn By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.
Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.
Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
- Other Names / Subsidiaries
- Avista Capital Partners
- Avista Healthcare Public Acquisition Corporation
- GCM Holding Corporation
- Inform Diagnostics, Inc.
- Kramer Laboratories
- Miraca Life Sciences, Inc.
- NuTech Medical
- NuTech Spine.